G
reat improvements have been made in the management of retinopathy of prematurity (ROP) since the initial therapeutic approach described in the Cryotherapy for Retinopathy of Prematurity study. 1,2 A more appropriate time for therapeutic intervention was defined by the Early Treatment for Retinopathy of Prematurity Randomized Trial, 3 and better screening strategies with the use of digital imaging systems are now available. 4, 5 All of this, together with the use of laser photocoagulation [6] [7] [8] [9] and vitreoretinal surgery, 10 -13 have contributed to significant increases in favorable outcomes and decreases in child blindness secondary to ROP.
Conventional therapy (laser photocoagulation) produces excellent results in zone II, but too many zone I cases still may have an unfavorable result with this treatment. 14 -18 Even in cases in whom there is a favorable anatomic result, functional outcome might be poor, mainly in aggressive posterior (ROP) zone I cases in whom vascular retinal development does not often reach the macular area. Currently, 90% of our patients with ROP correspond to low-birth-weight infants, and zone I now represents 35% of our ROPtreated cases.
The search for complementary or alternative treatments seems necessary for these infants. The wellknown role of vascular endothelial growth factor (VEGF) 19 as well as the availability of anti-VEGF drugs resulted in their use in ROP. Several reports involving the use of anti-VEGF drugs, specifically bevacizumab (Avastin, Genentech, San Francisco, CA), in cases with ROP have been published. 20 -23 After applying bevacizumab, successful results were achieved in three clinical situations before it was used as a first-line therapy. The drug was given to a group of patients after progression of the disease despite laser photocoagulation. A second group of patients included cases in which bevacizumab was used before vitrectomy because of the presence of retinal detachment and vascular activity when the patient was first seen. A third clinical situation involved posterior zone I cases without macular development in whom bevacizumab was used shortly after laser treatment. In these cases, we did not laser the area where the macula should develop, but instead, provided there was vascular activity, bevacizumab was injected after photocoagulation so as not to risk an unfavorable result because of insufficient laser treatment. This study reports a noncomparative, consecutive case study of 12 eyes with type 1 ROP treated with only one intravitreal injection of bevacizumab (Avastin).
Methods
Between August and December 2008, 12 eyes of 7 premature infants with type 1 ROP were treated consecutively with a single intravitreal injection of bevacizumab (0.625 mg). Type 1 ROP was defined according to the Early Treatment of Retinopathy of Prematurity Study 3 as one of the following conditions: zone I, any stage ROP with plus disease; zone II, stage 3 ROP without plus disease; or zone III, stage 2 or 3 ROP with plus disease.
Bevacizumab injection was preferred to laser treatment in these patients because the disease was so posterior as to preclude macular vascularization, visualization was hindered by a persistent tunica vasculosa lentis and vitreous haze, or they were too ill for laser treatment.
Two patients were screened by the authors and the other five referred from other neonatal units. All patients were treated within 72 hours of reaching type 1 ROP. No eyes with any stage of retinal detachment or congenital ocular anomaly were included. Preoperative examinations and follow-up were performed using indirect ophthalmoscopy and the RetCam Imaging System (Clarity Medical Systems, Pleasanton, CA).
The use of bevacizumab in our patients with ROP was discussed and approved by members of the National Neonatal Network. In all cases, written informed consent form was obtained from the guardians before the injections were administered.
The injections were administered in an operating room under the care of a pediatric anesthesiologist. Sterile unit doses of bevacizumab (Avastin) were prepared in a compounding pharmacy under aseptic conditions and placed in a tuberculin syringe. A dose of 0.625 mg was injected 1 mm posterior to the limbus after the instillation of 10% povidone-iodine. Besides systemic and local perioperative complications, we looked for complications specifically related to intravitreal injections.
Results
This series included 12 eyes of 7 premature infants, 5 boys and 2 girls. The infants weighed between 600 and 1,100 g (mean, 846.6 g). The gestational age ranged from 23 weeks to 28 weeks (mean, 25.6 weeks) ( Table 1) .
Nine eyes (75%) had zone I ROP. Of these, three were classified as aggressive posterior ROP. Three of the 12 eyes (25%) had zone II ROP. Bevacizumab was injected, on average, at 34 weeks for zone I cases and at 40 weeks for zone II cases. All eyes showed regression of the disease with no need for additional treatment.
We observed that the vascularization of the retina after the regression of the ROP after the bevacizumab injection followed a normal, although slower pattern with no evidence of vascular arrest or persistent cicatricial changes. However, not all eyes had reached the ora during the follow-up period.
Regarding macular architecture, no evidence of macular drag or distortion was found nor were any persistent cicatricial changes observed in this series of cases. No complications attributable to the bevacizumab were seen in any of our patients. An epiretinal hemorrhage was seen in one eye as a consequence of the injection procedure. The hemorrhage spontaneously reabsorbed without consequence. 
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Patient 1 was born at 28 gestational weeks. This case had posterior zone I ROP (aggressive posterior ROP) and developed type 1 ROP at 32-weeks postmenstrual age, 4 weeks after birth. On the day of the bevacizumab treatment, retinal vascularization did not even reach the macular area ( Figure 1A) . At 35.6-weeks postmenstrual age, retinal vessels reached the foveal area ( Figure 1B) . At 46-weeks postmenstrual age (14 weeks after the bevacizumab injection), retinal vascularization reached zone III ( Figure 1C) .
Patient 2 also presented zone I ROP, and the bevacizumab injection was administered at 32-weeks postmenstrual age, when the baby developed type 1 ROP (Figure 2A) . One week after the procedure, a total regression of the vascular activity at the anterior segment was observed ( Figure 2B ). There was a small epiretinal hemorrhage that was spontaneously reabsorbed. At 43-weeks postmenstrual age, the retinal vascularization reached zone III ( Figure 2C) .
The left eye of patient 3 presented a posterior zone I ROP, and bevacizumab was given at 34-week postmenstrual age. When the ridge started to regress, the limit between the vascular and avascular retina looked very neat, giving the impression of a neovascular strip advancing toward the avascular area ( Figure 3A) . Such a situation was observed in most cases. Normallooking vascularization reached zone III at 46-week postmenstrual age ( Figure 3B ). When this patient was referred, he had a vitreous hemorrhage in the right eye. Laser photocoagulation and bevacizumab were given at the same time. This eye had a favorable outcome and is not part of this series. 
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images of the right and left eyes taken 6 weeks after the bevacizumab injection. There is a marked vascular strip moving toward the avascular retina, which, previous to this study, would have prompted us to perform photocoagulation.
Patient 6 was a sick baby (sepsis, patent ductus arteriosus, severe pulmonary dysplasia); there was evidence of fibrosis at the time of treatment at 40.3-week postmenstrual age ( Figure 6A ). Regression was slower, and after 3-week postbevacizumab injections (43.3 weeks) ( Figure 6B ), anterior and posterior segment activities were still present. However, despite his poor systemic condition, there was no need for further treatment. Retinal vascularization reached zone III at 48.3 weeks ( Figure 6C ). Patient 7 was born at 24 weeks and weighed 600 g. She developed a zone II, type 1 ROP; bevacizumab was injected into the right eye at 40-weeks postmenstrual age with complete regression of the disease.
Discussion
Retinopathy of prematurity represents an important cause of pediatric blindness 24 in the world. The more posterior forms of the disease may have bad outcomes despite adequate treatment. 14 -18 Hence, the use of anti-VEGF drugs in the context of a vasoproliferative disorder was a logical approach. Good results have been obtained in patients with wet macular degeneration and diabetic retinopathy 25, 26 and also in a series of patients with ROP. 20 -23 This clinical information, together with the good results that we obtained with the bevacizumab injections as a complementary treatment before this series, 
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led us to the use of this drug as a first-line therapy. In this series, intravitreal anti-VEGF drugs allowed a favorable outcome in all cases with no additional treatment required. Laser therapy, however, is a destructive procedure. Therefore, if the same results can be obtained with this more conservative treatment, then many potential benefits may be obtained by using such a therapy, including more visual field and less refractive errors together with overall better vision for these eyes.
The specific clinical situations of these cases either prevented the use of laser treatment or the likelihood of a favorable outcome was too reduced. This, added to our step approach experience, supported the choice of offering a bilateral treatment.
Notwithstanding this, potential systemic side effects from the use of anti-VEGF drugs in infants remain a big concern. Monitoring of possible central nervous system, cardiac, or renal adverse effects probably should be part of any prospective trial of anti-VEGF agents for ROP. Nonetheless, we have seen no complications attributable to the bevacizumab injections in any of our patients. Doubtless, many questions are raised by this and other similar studies. What role will bevacizumab play in ROP? Are there any systemic side effects that are not yet known? Will bevacizumab prove to provide better functional outcomes?
For the time being, we believe that photocoagulation for type 1 ROP might not be the best first-line therapy for every case. Furthermore, the availability of anti-VEGF drugs forces us to establish the best choice for each patient. Given the available data, bevacizumab injection may be currently preferred to laser treatment in patients with disease that is too posterior as to preclude macular vascularization, visualization is hindered by a persistent tunica vasculosa lentis and vitreous haze, or they are too ill for laser treatment. Developing studies might expand these indications.
In conclusion, intravitreal bevacizumab is a useful therapy for type 1 ROP. However, additional studies need to be performed to define the role of bevacizumab as the first-line therapy, in combination with laser, or after the failure of laser photocoagulation.
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